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E-mail address: neville.vassallo@um.edu.mt (N. VaAggregation of alpha-synuclein (aS) into oligomers is critically involved in the pathogenesis of
Parkinson’s disease (PD). Using confocal single-molecule ﬂuorescence spectroscopy, we have stud-
ied the effects of 14 naturally-occurring polyphenolic compounds and black tea extract on aS oligo-
mer formation. We found that a selected group of polyphenols exhibited potent dose-dependent
inhibitory activity on aS aggregation. Moreover, they were also capable of robustly disaggregating
pre-formed aS oligomers. Based upon structure–activity analysis, we propose that the key molecular
scaffold most effective in inhibiting and destabilizing self-assembly by aS requires: (i) aromatic ele-
ments for binding to the aS monomer/oligomer and (ii) vicinal hydroxyl groups present on a single
phenyl ring. These ﬁndings may guide the design of novel therapeutic drugs in PD.
Structured summary of protein interactions:
Alpha-synuclein binds to Alpha-synuclein by biophysical (View Interaction 1, 2)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Convergent genetic, biochemical and animal studies over the
past decade strongly suggest that the aggregation of the 140-resi-
due pre-synaptic alpha-synuclein (aS) protein plays a fundamental
role in the etiology and pathogenesis of Parkinson’s disease (PD)
and related disorders [1]. These disorders are in fact collectively
known as ‘‘a-synucleinopathies’’, with PD being the most common
movement disorder [2]. Motor symptoms in PD reﬂect the severe
degeneration of dopaminergic neurons in the substantia nigra pars
compacta. The critical etiological link between aS aggregation and
toxicity to dopaminergic neurons was recently demonstrated
in vivo in a transgenic Drosophila model of the disorder [3]. Patho-
genesis of PD thus appears to be linked to conditions that increasechemical Societies. Published by E
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ssallo).the propensity for aS to aggregate and form ﬁbrils [4]; among
these: an increase in the intracellular concentration of aS (e.g. by
increased gene copy number) [5,6], missense mutations [7], oxida-
tive modiﬁcations [8,9], phosphorylation [10], the presence of
metal ions (e.g. Fe3+) [11], and interaction with phospholipid
membranes [12].
A lot of attention is therefore being directed at the development
of molecular inhibitors of aS aggregation for the prevention and
treatment of PD [13]. Indeed, an important class of compounds
found to be protective against aS ﬁbrillation is that of the polyphe-
nols, which are important beneﬁcial constituents in human diet
and medicinal plants [14]. Polyphenols are abundant in a wide
range of fruits, vegetables and beverages, including tea, red wine,
apples, berries, and strawberries. The daily average polyphenol in-
take is difﬁcult to estimate, but is supposed to average 200–500 mg
per day [14]. Polyphenolic compounds identiﬁed with anti-ﬁbrillo-
genic and ﬁbril-destabilizing effects for aS include baicalein (Baic)
[15], epigallocatechin gallate (EGCG) [16,17], rosmarinic acid (RA)
[18], tannic acid (TA), nordihydroguaiaretic acid (NDGA), curcu-
min, myricetin (Myr), kaempferol, catechin, and epi-catechin
[19]. Additional studies showed that several polyphenols inhibited
aS ﬁlament assembly by forming soluble, non-cytotoxic, oligo-
meric complexes with the aS protein [16,20–22]. Even more recent
ﬁndings suggest that EGCG is a powerful remodelling agent oflsevier B.V. All rights reserved.
Table 1
Description and physiochemical proﬁles of the 15 phenolic compounds used in this study.
Name of compound Class/
description
MW c Log P* Sources
Apigenin (Api) Flavone 270.2 2.00 Chamomile, celery, parsley
Baicalein (Baic) Flavone 270.2 2.69 Isolated from the roots of Scutellaria baicalensis
Black tea extract (BTE) >80% theaﬂavins – – Black tea
()-Epigallocatechin gallate (EGCG) Flavanol 458.4 2.64 White tea, green tea, black tea, grapes, wine, apple juice, cocoa, lentils, black-eyed peas
Genistein (Gen) Isoﬂavone 270.2 1.94 Soy, alfalfa sprouts, red clover, chickpeas, peanuts, other legumes
Ginkgolide B (Gink) – 424.4 -2.07 Isolated from the leaves of Ginkgo biloba
Morin (Mor) Flavonol 302.2 1.88 Isolated from Maclura pomifera, Maclura tinctoria and from leaves of Psidium guajava
Myricetin (Myr) Flavonol 318.2 1.50 Grapes, walnuts
Nordihydroguaiaretic acid (NDGA) Stilbene 302.4 4.34 Isolated from the leaves of Larrea tridentata
Purpurogallin trimethyl ether (Purp) Lignin 262.3 N/A –
Quercetin (Quer) Flavonol 338.3 1.80 Red/yellow onions, tea, wine, apples, cranberries, buckwheat, beans
Resveratrol (Resv) Stilbene 228.3 3.11 Grape skins and seeds, wine, nuts, peanuts
Rosmarinic acid (RA) Phenolic acid 360.3 1.64 lemon balm, rosemary, oregano, sage, thyme, peppermint
Scutellarein (Scut) Flavone 286.2 2.39 Isolated from the roots of Scutellaria lateriﬂora
Tannic acid (TA) Phenolic acid 1701.2 7.07 Nettles, tea, berries
The 15 phenolic compounds used in this study are listed together with their molecular weight (MW), calculated partition coefﬁcient (c Log P) and sources. Refer to Fig. 4 for
the chemical structures of the compounds.
* The calculated Log P value of a compound is the logarithm of its partition coefﬁcient between n-octanol and water, and is therefore a measure of the molecule’s
hydrophobicity. Hydrophobicity inﬂuences drug absorption, bioavailability, metabolism, and toxicity of the molecule. Most drugs on the market have a c Log P of 0–5.0.
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ler, amorphous aggregates [17].
In this study, we wanted to make use of the structural diversity
of natural polyphenols to deﬁne key molecular scaffolds most
effective in inhibiting oligomer formation by alpha-synuclein
and/or disaggregating pre-formed oligomers. Fourteen polypheno-
lic compounds and black tea extract (BTE) (Table 1) were
systematically tested using confocal single-particle ﬂuorescence
techniques. In recent years, ﬂuorescence correlation spectroscopy
(FCS), ﬂuorescence-intensity distribution analysis (FIDA) and scan-
ning for intensely ﬂuorescent targets (SIFT) have been recognised
as powerful tools for highly sensitive analysis of aggregation pro-
cesses in neurodegenerative diseases, including detection and
characterization of synuclein oligomers [23–25]. Importantly, this
technique allowed us to use nanomolar and low micromolar con-
centrations of aS and compounds. The fact that a diverse group
of polyphenols were analyzed enabled us to gain insight into par-
ticularly important structure–activity relationships. We also
looked at the controversial issue of whether the anti-amyloid ef-
fects of polyphenols are related, or not, to their antioxidant or
metal-ion chelation activities.
2. Materials and methods
2.1. Expression, puriﬁcation and labeling of recombinant alpha-
synuclein
Expression and puriﬁcation of recombinant aS was performed
as described previously by Kostka et al. [25]. Brieﬂy, pET-5a/a-
Synuclein (136TAT) plasmid (wt-plasmid a kind gift by Philipp
Kahle; the 136-TAC/TAT-mutation was performed by Matthias
Habeck) was used to transform Escherichia coli BL21(DE3)pLys
(Novagen, Madison, WI, USA), and expression was induced with
isopropyl b-D-thiogalactopyranose (IPTG) for 4 h. Cells were har-
vested, resuspended in 20 mM Tris and 25 mM NaCl, pH 8.0 and
lysed by boiling at 95 C for 30 min in a water bath. The lysate
was centrifuged at 17 000 g and 4 C for 15 min and the superna-
tant was ﬁltered and loaded into a HiTrap Q HP column (5 ml, GE
Healthcare). After elution, it was ultra-centrifuged at 40 000 g
and 4 C for 45 min and the supernatant concentrated using Viva-
spin 2 columns (MWCO 3 kDa). Afterwards the synuclein-fraction
was gel ﬁltrated over a Superdex 75 prep grade column (25 ml,GE Healthcare) with 20 mM Tris and 150 mM NaCl, pH 7.0 as run-
ning buffer to separate monomeric and oligomeric a-synuclein by
size. The protein concentration was determined in a standard
Bicinchoninic Acid (BCA)-solution assay. Aliquoted protein was
stored at 80 C after freezing in liquid nitrogen.
2.2. Fluorescent labeling of aS
Protein labeling by ﬂuorophores was performed as previously
described [25]. Brieﬂy, aS was labeled with Alexa Fluor-488-O-suc-
cinimidylester (‘‘green’’) and Alexa Fluor-647-O-succinimidylester
(‘‘red’’) (Invitrogen), respectively. Unbound ﬂuorophores were sep-
arated by two ﬁltration steps in PD10 columns (Sephadex G25;
Amersham Biosciences). Quality control of labeled aS was per-
formed by FCS measurements. To avoid repeated freeze/thawing,
the puriﬁed recombinant ﬂuorescently labeled monomeric aS
stocks were divided into smaller aliquots of 5–10 ll, and stored
at 80 C.
2.3. Confocal single particle analysis
FIDA and SIFT measurements were carried out on an Insight
Reader (Evotec-Technologies, Hamburg, Germany) with dual color
excitation at 488 and 633 nm. Excitation power was 200W at
488 nm and 300 lW at 633 nm. All measurements were performed
at room temperature. The ﬂuorescence signal was analyzed by FIDA
using FCSPP evaluation software version 2.0 (Evotec-Technologies).
For FIDA and SIFT analysis, ﬂuorescence from the two different
ﬂuorophores was recorded simultaneously with two single-photon
detectors; photons were summed over time intervals of constant
length (bins) using a bin length of 40 ls. The frequency of speciﬁc
combinations of ‘‘green’’ and ‘‘red’’ photon counts was recorded in
two-dimensional intensity distribution histograms. Evaluation of
SIFT data in two-dimensional intensity distribution histograms
was performed by summing up the numbers of high intensity bins
each of 18 equally sized sectors using a 2D-SIFT software module
(Evotec-Technologies). For threshold setting, non-aggregated refer-
ence samples were used. This single molecule detection technology
allows highly sensitive analysis of protein aggregation by changes
in the brightness of individual particles. FIDA is able to distinguish
between differently bright species and, as such, gives indirect infor-
mation about particle sizes.
Fig. 1. Upper panel: SIFT two-dimensional intensity distribution histograms show-
ing the induction of small type-I oligomers (using 1% DMSO) and larger type-II
aggregates (using 1% DMSO and 10 lM Fe3+) from aS monomers (control). Lower
panel: SIFT two-dimensional intensity distribution histograms showing the inhibi-
tion of both types of oligomeric assemblies upon incubation with 3 lg/ml black tea
extract (BTE).
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A ﬁvefold stock solution of ﬂuorescently labeled aS was pre-
pared by mixing aS labeled with Alexa-488 and aS labeled with
Alexa-647. The concentrations of aS-Alexa-488 and aS-Alexa-647
were adjusted to approximately 10 molecules per focal volume
and 15 molecules per focal volume, respectively. Aggregation
was started by diluting the stock solution in 50 mM Tris–HCl buffer
(pH 7.0) containing ﬁnal 1% DMSO and 20–30 nM labeled aS in a
total volume of 20 ll. FeCl3 was used at a ﬁnal concentration of
10 lM. The aggregation reaction was typically complete in
10 min, but the plate was left for another 20 min at room temper-
ature to minimize variance in measurements. All experiments
were performed in 96-well-plates with a cover slide bottom.
2.5. Compound testing
All polyphenol compounds and black tea extract (Table 1) were
obtained from Sigma–Aldrich, Germany; except for scutellarein
(Scut) which was purchased from Pharmasciences Laboratories,
France. N-Acetyl-L-cysteine (N-acetylC), Vitamin C (VitC) and Des-
ferrioxamine (Desf) were also obtained from Sigma. Compounds
were dissolved in dimethylsulfoxide (DMSO) and kept as 10 mM
stock solutions at 20 C to maintain maximal stability. During
the experiments they were used immediately after thawing and
kept away from light. Compound screening was typically done at
10 lM (3 lg/ml for BTE) in a total assay volume of 20 ll. We ini-
tially conﬁrmed that all compounds did not autoﬂuoresce or
quench at the diluted concentration (data not shown). To assay
for inhibitory activity, compounds were added to monomeric aS
in 50 mM Tris–HCl buffer (pH 7.0), before starting aggregation
with 1% DMSO ± 10 lM FeCl3. To test for disaggregating activity,
the compounds were added to pre-formed oligomeric aS. In both
cases, after initiating aggregation the plate was left for 30 min
at room temperature. The average SIFT signal from samples (in
triplicate) was expressed as a percentage of the average signal from
aS aggregation control wells. SIFT signals were generated by sum-
ming up the photon counts from the ‘‘green’’ and ‘‘red’’ channels
for all bins above cut-off (threshold) level.
2.6. Statistical analysis
Results were expressed as the means and the standard devia-
tion (S.D.) values, with n as the number of experiments. Calculation
of IC50 values from dose-dependency curves was performed using
an on-line software facility (http://bsmdb.tmd.ac.jp:3000/cbdb/
ic50). Differences between means were determined by unpaired
Student’s t test. In all analyses, the null hypothesis was rejected
at the 0.05 level.
3. Results and discussion
3.1. Biophysical characterization of the aS aggregates
Using three independent single particle-based methods, we re-
cently described a robust in vitro multistep aggregation model for
aS [25,26]. In this model, incubation of nanomolar quantities of aS
with 1% DMSO for 10 min was sufﬁcient for maximal conversion of
aS monomers into small aggregates, termed ‘type-I’ oligomers
(Fig. 1, upper panels). Cross-correlation analysis indicated a size
of 20 monomers for these oligomers [25]. Addition of 10 lM
Fe3+ ions in the aggregation assay resulted in the formation of lar-
ger (>100meres) ‘type-II’ oligomers (Fig. 1, upper panels). AFMmea-
surements agreed with the confocal single particle ﬂuorescence
results [25]. Both type-I and type-II oligomer species are on-pathway to amyloid ﬁbrils, as indicated by Thioﬂavin T assays.
The robust aS aggregation model thus characterized is ideally
suited for application in screening of small-molecule compound
libraries for aggregation inhibitors.
3.2. Select polyphenols and BTE potently inhibit formation of type-I
and type-II aS oligomers
We ﬁrst tested the ability of 13 polyphenols and black tea ex-
tract (Table 1) to antagonize the aggregation of alpha-synuclein
into type-I oligomers (Fig. 2A). The degree of inhibition by the var-
ious compounds was wide-ranging, from very strong inhibition
(e.g. BTE = 0.4% and Mor = 0.7%), to strong (e.g. Myr = 10%,
Quer = 12%), moderate (e.g. RA = 45%, Resv = 47%), and relatively
weak (e.g. Gen = 68.6%, Api = 65.1%); this feature would later prove
useful in deducing structure–activity relationships. Nine com-
pounds – namely, BTE (see also Fig. 1, lower panels), Mor, TA, Baic,
NDGA, EGCG, Gink, Myr and Quer – blocked type-I aS oligomer for-
mation to less than 20% of the control value, the latter representing
aggregation in the presence of DMSO only. Dose-dependency
curves were also performed on seven of these anti-aggregation
compounds, using compound concentrations between 12.5 nM
and 10 lM. The following IC50 values were obtained: TA, 61 nM;
NDGA, 77 nM; EGCG, 0.79 lM; BTE, 0.81 lM; Baic, 2.03 lM; Myr,
3.57 lM; Mor, 4.24 lM (Fig. 7). Aggregation of aS occurs more
strongly and results in larger type-II oligomers when ferric iron
is added to the reaction mixture (Fig. 1). Thus, we selected the best
ten compounds from the previous assay, and assessed their ability
to antagonize aS aggregation in the presence of Fe3+ ions as well. A
broad range of inhibition was again observed, with six compounds
blocking type-II aS oligomer formation to lower than 20% of the
control value (Fig. 2B): Baic (2.62 ± 0.6%), NDGA (7.96 ± 1.1%),
Myr (10.12 ± 0.7%), EGCG (10.13 ± 1%), BTE (15.9 ± 4.4%), and TA
(18.9 ± 1%). Hence, ﬁve polyphenols – namely, Baic, EGCG, Myr,
NDGA and TA – as well as BTE could be selected as compounds that
potently interfere with the assembly of alpha-synuclein into mul-
timeric oligomers, with IC50 in the low micromolar range. Other
studies have shown that polyphenols can induce oligomer forma-
tion. EGCG, for instance, promoted the folding of aS monomers into
Fig. 2. Inhibition of aS aggregation by polyphenols and black tea extract.
Polyphenols and BTE were tested for their ability to inhibit de novo aggregation
of aS into type-I (A) or type-II (B) oligomers. Reaction mixtures containing
monomeric aS and 1% DMSO in 50 mM Tris–HCl buffer (pH 7.0) (A), or 1% DMSO
and 10 lM FeCl3 in 50 mM Tris–HCl buffer (pH 7.0), were assayed by SIFT analysis
following incubation at room temperature in the presence of 10 lM polyphenols
and 3 lg/ml BTE. Average type-I oligomer formation induced by 1% DMSO alone
(aS + DMSO) was regarded as 100% in (A); average type-II oligomer formation
induced by 1% DMSO and 10 lM Fe3+ (aS + DMSO + Fe) was regarded as 100% in (B).
Values represent means ± S.D. (nP 3).
Fig. 3. Disaggregation of type-I (A) and type-II (B) aS oligomers by polyphenols and
black tea extract. Complete aggregation of alpha-synuclein in each well was ﬁrst
conﬁrmed by SIFT measurements (100% control), before adding polyphenols
(10 lM) and BTE (3 lg/ml). SIFT analysis was conducted again after 30 min in the
presence of compounds. Average type-I oligomer formation induced by 1% DMSO
alone (aS + DMSO) was regarded as 100% in (A); average type-II oligomer formation
induced by 1% DMSO and 10 lM Fe3+ (aS + DMSO + Fe) was regarded as 100% in (B).
Values represent means ± S.D. (n = 4).
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to ﬁbrillogenesis [16]. Similarly, Baic induced the formation of,
and stabilized, aS oligomers consequently preventing their ﬁbrilli-
zation [21]. Nevertheless, very strong inhibition of aS oligomeriza-
tion by the potent compounds was evident in our single-molecule
approach.
3.3. Disaggregation of pre-formed aS oligomers by polyphenols and
BTE
The 13 polyphenols and BTE listed in Table 1 (excluding scutel-
larein) were next tested for their ability to disaggregate pre-
formed aS oligomeric structures, the latter induced either by
DMSO alone (type-I; Fig. 3A), or with the inclusion of ferric iron
(type-II; Fig. 3B). It was found that Baic, EGCG, Myr, NDGA and
BTE signiﬁcantly disrupted both types of oligomers to <20% of their
initial aggregated state. We also carried out dose-dependency
experiments (0.01 – 10 lM) to determine IC50 values for disaggre-
gation potency: Baic, 0.85 lM; EGCG, 0.26 lM; Myr, 2.52 lM;
NDGA, 20 nM; TA, 67 nM; BTE, 0.79 lM (Fig. 7). Interestingly, the
two compounds having the lowest IC50 values for disaggregation,
NDGA (IC50 = 20 nM) and EGCG (IC50 = 260 nM), show ‘‘linear’’
dose–response curves. This contrasts with the sigmoidal shapes
of the other compound curves. An effect was observed even at
the lowest concentrations of 10 nM for NDGA and 100 nM for
EGCG, with a linear increase (on a logarithmic scale) to almost100% effect at 10 lM. The implication is that disassembly of the
aS aggregate structures occurred even at concentrations just above
zero and increased with the concentration of the compound.
3.4. Overall compound potency correlates with number of vicinal
hydroxyl groups on a phenyl ring
At this stage, we therefore concluded that Baic, EGCG, Myr,
NDGA and BTE could be classiﬁed as being the best combined
inhibitors and disaggregators of aS oligomers. On the other hand,
compounds like purpurogallin trimethyl ether (Purp), Api, Gen
and Resv, which were relatively weak inhibitors, were also poor
disaggregators of DMSO-induced synuclein oligomers. With re-
gards to Fe-induced oligomers, Gink and RA were similarly weak
in both inhibition and destabilization of larger type-II synuclein
species. Thus, a pattern was emerging suggesting an important
structure–function relationship: the ranking of overall compound
potency (i.e. inhibition and disaggregation) in our aggregation
model could be fairly accurately predicted based upon the number
of hydroxyl groups present on a single phenyl ring, as follows: tri-
hydroxy- > dihydroxy- > monohydroxy-phenyl ring (refer to Fig. 4
for grouping of compounds according to their chemical structures).
The favouring of trihydroxyphenyl rings is made especially clear
when comparing Baic and Api, the latter being much weaker in
inhibiting or disaggregating type-I synuclein oligomers. Structur-
ally, both have the same ﬂavone structure and both possess a total
of three –OH groups. The difference lies in that whilst Baic has all
three –OH groups attached to the same benzene ring, Api has a
dihydroxyphenyl at one end of the molecule and a hydroxyphenyl
ring at the other end (Fig. 4). Therefore, since both compounds
Fig. 4. Two-dimensional chemical structures of the polyphenolic compounds used in this study, grouped according to structure–activity data.
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the total number of –OH groups present in the molecule that is
important for anti-aggregate activity, but rather the distribution
of the –OH groups, most signiﬁcantly the presence of three vicinal
hydroxyl groups as in baicalein.
To test this hypothesis another polyphenol with a trihydroxy-
phenyl ring, Scutellarein (Scut; Fig. 4), was selected for direct
comparison to Baic and Api. Indeed, in agreement with the struc-
ture–activity hypothesis outlined above, Scut behaved in a similar
way to Baic with regards to both inhibition of type-II synuclein
oligomers and disaggregation of pre-formed oligomers, whereasFig. 5. The ﬂavones apigenin (Api), scutellarein (Scut) and baicalein (Baic) inhibit
formation of, and disaggregate, type-II aS oligomers. Reaction mixtures containing
aS and 10 lM polyphenol in 50 mM Tris–HCl buffer (pH 7.0) were assayed by SIFT
analysis following incubation at room temperature, thus determining the inhibitory
activity of the compounds (black). In the disaggregation experiments, the
polyphenols were added to pre-formed type-II oligomers (gray). Average type-II
oligomer formation induced by 1% DMSO and 10 lM Fe3+ was regarded as 100% (aS
oligo). Values represent means ± S.D. (n = 2).Api was much less effective (Fig. 5). One can point out the apparent
exception of NDGA to this insight into structure–activity relation-
ship. NDGA, which does not have three adjacent –OH groups, is
nonetheless one of the most effective compounds overall. How-
ever, NDGA has a very symmetrical structure with dihydroxy-
phenyl rings at both ends of the molecule; perhaps the structural
symmetry confers an advantage with regards to possible orienta-
tions when binding to the aS molecules. Our data is in agreement
with a related ﬁnding that dopamine and derivative compounds
that have vicinal dihydroxy groups were shown to be effective
inhibitors of aS ﬁbrillization [9].Fig. 6. The iron chelator desferrrioxamine (Desf), and the antioxidants N-acetyl-
cysteine (N-acetylC) and vitamin C (VitC) do not affect aS aggregation into type-II
oligomers. Reaction mixtures containing monomeric aS, 1% DMSO and 10 lM FeCl3
in 50 mM Tris–HCl buffer (pH 7.0) were assayed by SIFT analysis following
incubation at room temperature in the presence of 100 lM compounds. Average
type-II oligomer formation induced by 1% DMSO and 10 M lFe3+ was regarded as
100% (aS oligo). Values represent means ± S.D. (n = 2).
Fig. 7. Dose-dependent inhibition and disaggregation of aS oligomer formation, with determination of IC50 values. The reaction mixtures containing monomeric aS, 1% DMSO
in 50 mM Tris–HCl buffer (pH 7.0), and 0.0125, 0.025, 0.05, 0.01, 0.1, 1, 5 or 10 lM compound were incubated at room temperature for 10 min. Average oligomer formation
induced by DMSO, and without compounds, was regarded as 100%. Each point represents the mean of three independent experiments. The graphs and calculated IC50 values
were obtained as described in Section 2.
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iron chelation mechanisms
An issue we wanted to address was whether the well-known
antioxidant, and even metal-ion chelating, activities of polypheno-
lic compounds could be contributing to their observed anti-
aggregation effects. We found no detectable inhibitory activity by
the classical antioxidants N-acetylC (100 lM) and VitC (100 lM),
or by the powerful iron chelator Desf (100 lM) on aS aggregation
induced by DMSO and Fe3+ ions (Fig. 6). Similarly, disassembly of
preformed type-II oligomers was not evident by 100 lM N-acetylC
(173 ± 27%) or VitC (100 ± 15%); rather, N-acetylC appeared to
actually enhance the aggregation. In conclusion, it appears unlikely
that antioxidant or metal-chelating mechanisms are relevant for
the antagonistic effects of polyphenols (all used at only 10 lM)
on aS oligomerization. Moreover, there is no trend between our
compound classiﬁcation of anti-amyloid effects and published data
on the anti-oxidant potencies of the studied phenols [27,28].
4. Conclusions
Using confocal single-molecule ﬂuorescence spectroscopy, we
have studied the effects of 14 phenolic compounds and black tea ex-
tract speciﬁcally on aS oligomerization induced by organic solvent.
We establish that a select group of small-molecule polyphenols hav-
ing three vicinal hydroxyl groups (Baic, Scut, Myr, EGCG), together
withNDGA and black tea extract, constitute a set of compounds that
can potently hinder aS aggregation into oligomers as well as disag-
gregate pre-formed aS oligomers, with IC50 in the submicromolar
(<1 lM) range. The physiological concentration of aS is estimated
to be 1 lM in normal human brain and 70 pM in cerebrospinal
ﬂuid [29]. Similarly, it is not expected that polyphenols or theirmetabolites can attain levels in the brain higher than 10 lM [30].
For these reasons, we believe that the conclusions from our study,
as they stand, are already potentially relevant to the in vivo sce-
nario. Moreover, by structure–activity analysis, we propose that
the physicochemical proﬁles of potent compounds require: (i) aro-
matic recognition elements that would allow non-covalent binding
to the amyloidogenic core of the aSmonomer/oligomer [31] and (ii)
hydroxyl groups (especially the presence of three > two > one –OH
groups on the same ring structure) that would hinder the progress
of the self-assembly process and/or destabilize its structure. For
instance, molecular dynamics simulations recently showed that
Myr destabilized ordered amyloid oligomers by weakening inter-
strand hydrogen bonds [32]. Notwithstanding, it cannot be ex-
cluded that the polyphenols can also bind to other sites of the aS
protein. For example, Zhou et al. [33] have suggested that the
polyphenol DOPAC (3,4-dihydroxyphenylacetic acid), a product of
dopamine metabolism, inhibits ﬁbrillation of aS by binding non-
covalently to the N-terminal region.
Regarding the general usefulness of polyphenolic compounds in
terms of drug development, it has to be ﬁrst pointed out that poly-
phenols commonly display reduced oral bioavailability, increased
metabolic turnover, and lower permeability through the blood–
brain barrier [34]. The maintenance of a high concentration in plas-
ma normally requires repeated ingestion of the polyphenols over
time, whilst the biological activities of the metabolites may differ
from the parent compounds [35]. Notwithstanding, in a large epi-
demiological study conducted in Asia, black tea showed an inverse
association with Parkinson’s disease risk that was not confounded
by other factors, like total caffeine intake or tobacco smoking [36].
Oral administration of the phenolic compounds myricetin and
NDGA, both of which were found to have potent activity in our as-
says, was successful in modulating amyloid aggregation pathways
M. Caruana et al. / FEBS Letters 585 (2011) 1113–1120 1119in vivo and prevent the development of AD neuropathology in mice
[37]. Another potent polyphenol singled out in our study, EGCG,
has been administered orally in drinking water to AD transgenic
mice resulting in a reduced plaque burden and cognitive beneﬁt
[38]. Hence, it cannot be excluded a priori that dietary supplemen-
tation with polyphenols provides an effective treatment modality
for neurodegenerative disorders of the amyloid type. Moreover,
systemic oral bioavailability of EGCG in rats can be increased more
than twofold by formation and administration of nanolipidic EGCG
particles [39]. Such strategies allow EGCG, and possibly other poly-
phenols, to achieve therapeutically effective concentrations in clin-
ical settings.
Certainly, the conclusions from our study, together with others
from previous reports, put forward a strong case for testing the
efﬁcacy of a select group of lead polyphenols in transgenic mouse
models of PD. Thus, baicalein, scutellarein, myricetin, EGCG, NDGA
and black tea extract are all valid candidates for further assessment
with regard to inhibition of aS oligomer formation in vivo, the lat-
ter representing the most likely toxic molecular species of aS [40].
Finally, detailed investigations into the structure–activity relation-
ships of natural products outlined above may guide the design of
novel therapeutic drugs in Parkinson’s disease which possess en-
hanced properties in vivo (e.g. ability to penetrate the blood–brain
barrier), but which retain the bioactivity characteristic of the nat-
ural product scaffold.Acknowledgements
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